U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 10

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the application dated September 19, 2014,
1. Nordion (Canada) Inc.	3. License number 54-28275-02MD is amended in its entirety to read as follows:
2. 447 March Road Ottawa, Ontario, Canada K2K 1X8	4. Expiration date March 31, 2025
	5. Docket No. 03030793 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Iodine 123	A. Any	A. Not Applicable
B. Iodine 125	B. Any	B. Not Applicable
C. Iodine 131	C. Any	C. Not Applicable
D. Yttrium-90	D. Glass microspheres (Nordion (Canada), Inc., Model TheraSphere)	D. Not to exceed 540 millicuries per administration set

9. Authorized use:

A. through C. Pursuant to 10 CFR 32.72, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR Part 35.100, 35.200, 35.300 or under equivalent licenses of any Agreement State.

D. Pursuant to 10 CFR 32.74, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR 35.1000, or under equivalent licenses of any Agreement State.

CONDITIONS

10. The licensee may distribute material from 447 March Road, Ottawa, Ontario, Canada and 4004 Wesbrook Mall, Vancouver, British Columbia, Canada.

11. This license does not authorize possession or use of licensed material.

12. By April 1, 2016, provide evidence that you are registered or licensed with the U. S. Food and Drug Administration (FDA) as a drug manufacturer as required by 10 CFR 32.72(a)(2). Alternatively, you

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
54-28275-02MD

Docket or Reference Number
03030793

Amendment No. 10

may submit evidence from the FDA to support relief from this requirement.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 23, 2014 [ML14279A523]
B. Letter dated February 25, 2015 [ML15071A409]
C. Letter dated March 18, 2015

For the U.S. Nuclear Regulatory Commission

Original signed by Elizabeth Ullrich

Date March 18, 2015 By _____

Elizabeth Ullrich
Commercial, Industrial, R&D and Academic Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406